Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Between 1978 and 1983, 1127 patients with de-novo acute myeloid leukaemia (AML) were entered into the Medical Research Council (MRC)'s 8th AML trial. All received the same induction therapy consisting of daunorubicin, cytarabine, and 6-thioguanine--DAT (1 + 5). The 67% who entered complete remission were randomised to consolidation with two or six further courses of DAT. Adults under the age of 55 were randomised for central nervous system (CNS) prophylaxis with intrathecal cytarabine and methotrexate. Finally, those still in remission after 1 year of cytarabine and 6-thioguanine (AT) maintenance were randomised to receive either late intensification with cyclophosphamide, vincristine, cytarabine, and prednisolone (COAP) or continued AT. The median survival for the whole group was 12 months; the median duration of first remission was 15 months, with relapse-free survival at 5 years estimated at 18%. The factors most strongly associated with poor survival were performance status and age at presentation, but even among those over 60 years of age, half went into remission. Six courses of DAT consolidation gave a small advantage over two courses in reducing the number of late relapses but no significant survival advantage. Late intensification showed a marginally significant advantage over continued AT maintenance. The incidence of CNS relapse was low and unaffected by prophylaxis. The second remission rate varied from 10% when the first remission was shorter than 6 months to 61% when it had continued for more than 2 years. 40 patients received histocompatible allogeneic bone-marrow transplants in first remission. There was a high procedure-related death rate, particularly among patients over 30 years of age. Thus, initially at least, the transplanted group had shorter survival than a comparable group of chemotherapy-treated patients. Treatment specifications remained unchanged throughout the trial but those enrolled in the later half of the trial had a better (p = 0.003) survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In acute AML, complete remission to daunorubicin-and cytarabine-based chemotherapy occurs in 70% of patients % 60 years of age, but in only 45%-50% of individuals aged >60.263,264”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [263]
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
The clinical evaluation of chemotherapeutic agents in cancer
Karnofsky, D. A. (1949) · Medical Entomology and Zoology · Cited by 2,933
Marrow Transplantation for Acute Nonlymphoblastic Leukemia in First Remission
Thomas, E. D., Buckner, C. D., Clift, R. A., Fefer, A., Johnson, F. L., Neiman, P. E., Sale, G. E., Sanders, J. E., Singer, J. W., Shulman, H., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197909133011109 · Cited by 641
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B
Rai, K., Holland, J., Glidewell, O., Weinberg, V, Brunner, K., Obrecht, J., Preisler, H., Nawabi, I., Prager, D., Carey, R., et al. (1981) · Blood · doi:10.1182/blood.v58.6.1203.1203 · Cited by 532
Peto, R., Pike, M. C., Day, N., Gray, R. G., Lee, P. N., Parish, S., Peto, J., Richards, S. M., & Wahrendorf, J. (1980) · PubMed · Cited by 478
Algorithm AS 99: Fitting Johnson Curves by Moments
Hill, I. D., Hill, R., & Holder, R. L. (1976) · Applied Statistics · doi:10.2307/2346692 · Cited by 386
Büchner, T., Urbanitz, D., Hiddemann, W., Rühl, H., Ludwig, W. D., Fischer, J., Aul, H. C., Vaupel, H. A., Kuse, R., & Zeile, G. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.12.1583 · Cited by 362
Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update
Weinstein, H., Mayer, R., Rosenthal, D., Coral, F., Camitta, B., & Gelber, R. (1983) · Blood · doi:10.1182/blood.v62.2.315.315 · Cited by 277
8;21 translocation in acute granulocytic leukaemia: cytological, cytochemical and clinical features
Swirsky, D. M., Li, Y. S., Matthews, J. G., Flemans, R. J., Rees, J. K. H., & Hayhoe, F. G. J. (1984) · British Journal of Haematology · doi:10.1111/j.1365-2141.1984.tb03948.x · Cited by 238
Self-citation
Cited by
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899
Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I.-M., Head, D. R., Appelbaum, F. R., & Willman, C. L. (1997) · Blood · doi:10.1182/blood.v89.9.3323 · Cited by 859
Leith, C. P., Kopecky, K. J., Chen, I. M., Eijdems, L., Slovak, M. L., McConnell, T. S., Head, D. R., Weick, J. K., Grever, M. R., Appelbaum, F. R., et al. (1999) · PubMed · doi:10.1182/blood.v94.3.1086.415k32_1086_1099 · Cited by 573
Metadata
- Authors
- REES, J.
- Affiliations
- Medical Research Council (GB)
- Corresponding author
- REES, J
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1986-11
- Volume
- 328
- Issue
- 8518
- Pages
- 1236-1241
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2000838340
- Cited by
- 320
- References
- 25
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 5 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 3 · 2016: 5 · 2015: 3 · 2014: 6 · 2013: 3 · 2012: 1
- FWCI
- 10.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- acute myeloid leukemia, consolidation chemotherapy, CNS prophylaxis, maintenance chemotherapy, allogeneic bone marrow transplantation, relapse-free survival, prognostic factors, performance status, age at presentation, non-relapse mortality
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols, Central Nervous System Diseases, Child, Child, Preschool, Clinical Trials as Topic, Cytarabine, Daunorubicin, Drug Administration Schedule, Humans, Infant, Middle Aged, Neoplasm Recurrence, Local, Neoplasms, Prognosis, Random Allocation, Thioguanine, Leukemia, Myeloid, Acute, Bone Marrow Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial. https://app.cochat.ai/papers/10.1016/s0140-6736(86)92674-7
- The paper
- REES, J. (1986). Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial. The Lancet. https://doi.org/10.1016/s0140-6736(86)92674-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.